New study: surgical menopause linked to more severe genitourinary symptoms — what Canadian patients should know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

A study published June 10, 2026, in Menopause, the peer-reviewed journal of The Menopause Society, found that women who reached menopause through bilateral oophorectomy (surgical removal of both ovaries) had statistically significantly higher rates of genitourinary syndrome of menopause (GSM) symptoms and worse clinical exam scores than women who went through natural menopause, across a cohort of more than 400 postmenopausal women. For Canadian patients scheduled for hysterectomy or oophorectomy, the findings add weight to a conversation that many clinicians have not been having routinely: GSM is common, it is undertreated, and the surgical route to menopause makes it worse.

GSM is a chronic condition caused by estrogen deprivation in the tissues of the lower urinary tract and genitals after menopause. Reported prevalence ranges from 27% to 84% of postmenopausal women, yet it is frequently missed in routine care. For Canadians, that gap matters practically: access to GSM treatment varies by province, Health Canada has approved several local and systemic estrogen therapies for GSM, and the SOGC (Society of Obstetricians and Gynaecologists of Canada) has published guidance on menopause management that addresses genitourinary symptoms, though a dedicated surgical-menopause-specific GSM position statement has not yet been issued.

What this means in Canada

Health Canada has approved multiple treatments for GSM. Local vaginal estrogen options available in Canada include estradiol vaginal cream (Estrace vaginal cream), the estradiol vaginal ring (Estring), and prasterone (dehydroepiandrosterone, sold in Canada as Intrarosa), a vaginal insert approved specifically for dyspareunia (painful intercourse) due to menopause. Ospemifene (Osphena), an oral selective estrogen receptor modulator for GSM-related dyspareunia, is also approved by Health Canada. Systemic hormone therapy — estradiol tablets (Estrace), patches (Estradot, Climara), or gels (Estrogel) — can address GSM alongside other surgical menopause symptoms like hot flashes and sleep disruption.

Provincial coverage is inconsistent. In Ontario, OHIP does not cover the cost of hormone therapy drugs themselves; patients rely on the Ontario Drug Benefit (ODB) program if they qualify, or on private insurance. In Quebec, RAMQ covers some hormone therapy formulations for eligible patients. British Columbia's PharmaCare and Alberta's AHCIP have their own formularies, and coverage for specific GSM products differs. Patients should check their provincial formulary or speak with a pharmacist.

The SOGC's 2021 menopause guidelines recommend that clinicians ask about genitourinary symptoms at midlife visits and offer local vaginal estrogen as a first-line option for GSM, noting it carries a low systemic absorption profile. The SOGC has not yet issued a position statement specific to GSM severity in surgical versus natural menopause, so the new Menopause Society findings have not been formally incorporated into Canadian guidance as of this writing.

Canadian patients can access GSM assessment and treatment through their family physician, a gynaecologist, or through virtual menopause-focused platforms. Cleo, a Canadian women's-health platform, and Science & Humans (scienceandhumans.com), a Canadian telehealth service, both offer menopause consultations. Felix and Maple also connect Canadian patients with licensed clinicians for prescription renewals. US-only platforms such as Midi Health and Hone Health do not serve Canadian patients.

What the study found

Researchers compared GSM symptom frequency and standardized clinical exam scores between women who had undergone bilateral oophorectomy and women who had reached menopause naturally. The surgical menopause group showed significantly higher rates of vaginal dryness, pain during intercourse, pain during urination, reduced sexual desire, postcoital bleeding, and urinary frequency. Clinical exam scores, which reflect objective tissue changes, were also worse in the surgical group.

The mechanism is straightforward: surgical removal of both ovaries causes an immediate, steep drop in estrogen and testosterone, rather than the gradual hormonal decline of natural menopause. That abrupt withdrawal appears to accelerate and intensify the tissue changes that drive GSM.

The study's lead finding aligns with what The Menopause Society's medical director, Dr. Stephanie Faubion, described in the press release: "In women with surgical menopause, this may be even more critical and should prompt early evaluation and treatment of symptoms."

The researchers also noted that the results support a growing clinical preference for ovarian-conserving approaches during hysterectomy when it is medically safe to do so. Removing the uterus without removing the ovaries preserves hormonal function and may reduce GSM severity.

What Canadian patients should know

If you are scheduled for a hysterectomy, ask your surgeon explicitly whether your ovaries will be removed and what the hormonal consequences are. If bilateral oophorectomy is medically necessary, ask about initiating hormone therapy immediately after surgery rather than waiting for symptoms to develop. Early treatment is associated with better tissue outcomes.

If you have already had surgical menopause and are experiencing vaginal dryness, pain during sex, or urinary symptoms, bring it up at your next appointment. GSM does not resolve on its own and tends to worsen over time without treatment. Local vaginal estrogen is considered safe for most women, including many with a history of hormone-sensitive cancers, though that decision requires individual clinical assessment.

Provincial differences in drug coverage mean the out-of-pocket cost of GSM treatments varies. Intrarosa (prasterone) and Osphena (ospemifene), for example, may not be covered under all provincial plans and can cost between CAD $60 and $150 per month without coverage. Generic vaginal estradiol cream is generally less expensive. A pharmacist can help identify the lowest-cost covered option for your province.

Patients in rural or remote areas with limited access to gynaecology can request a referral to a menopause specialist or use a provincially licensed telehealth service for an initial consultation and prescription.

Limitations and open questions

The study involved more than 400 women, which is a reasonable sample for this type of comparison, but the researchers did not specify the racial, ethnic, or geographic composition of the cohort, which limits how broadly the findings can be applied. The study was observational, so it cannot prove that surgical menopause directly causes worse GSM outcomes independent of other factors such as age at surgery, duration since menopause, or prior hormone therapy use.

The SOGC has not yet issued guidance specific to GSM management in surgical menopause. Health Canada has not issued any new regulatory communication in response to this study. Whether provincial pharmacare programs will expand coverage for GSM treatments in light of accumulating evidence is an open question.

Longer-term data on whether early hormone therapy initiation after oophorectomy meaningfully reduces GSM severity compared to delayed treatment are still limited. The CIHR (Canadian Institutes of Health Research) has not announced dedicated funding for surgical-menopause-specific GSM research as of June 2026.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.